 |
 |

Safety and Efficacy of 2% Pirenzepine Ophthalmic Gel in Children With Myopia
A 1-Year, Multicenter, Double-Masked, Placebo-Controlled Parallel Study
R. Michael Siatkowski, MD;
Susan Cotter, OD;
Joseph M. Miller, MD;
Colin A. Scher, MD;
R. Stephens Crockett, PhD;
Gary D. Novack, PhD; for the US Pirenzepine Study Group
Arch Ophthalmol. 2004;122:1667-1674.
Objective To evaluate the safety and efficacy of the relatively selective M1 antagonist pirenzepine hydrochloride in slowing the progression of myopia in school-aged children.
Methods This was a parallel-group, placebo-controlled, double-masked study in healthy children, aged 8 to 12 years, with a spherical equivalent of 0.75 to 4.00 diopters (D) and astigmatism of 1.00 D or less. Patients underwent a baseline complete eye examination and regular examinations during a 1-year period. The setting was 13 US academic clinics and private practices. Patients were randomized in a 2:1 ratio to receive 2% pirenzepine ophthalmic gel or a placebo control twice daily for 1 year.
Results At study entry, the spherical equivalent was mean ± SD 2.098 ± 0.903 D for the pirenzepine group (n = 117) and 1.933 ± 0.825 D for the placebo group (n = 57, P = .22). At 1 year, there was a mean increase in myopia of 0.26 D in the pirenzepine group vs 0.53 D in the placebo group (P < .001). No patients in the placebo group and 13 (11%) of 117 patients in the pirenzepine group discontinued participation in the study because of adverse effects (5 [4%] of 117 due to excessive antimuscarinic effects).
Conclusions Pirenzepine is effective and relatively safe in slowing the progression of myopia during a 1-year treatment period.
Author Affiliations: Department of Ophthalmology, University of Oklahoma, and Dean A. McGee Eye Institute, Oklahoma City (Dr Siatkowski); Southern California College of Optomety, Fullerton (Dr Cotter); Departments of Ophthalmology, Optical Sciences, and Public Health, University of Arizona, Tucson (Dr Miller); Department of Ophthalmology, Childrens Hospital and Health Center, San Diego, Calif (Dr Scher); D.A.T.A., Inc, Mobile, Ala (Dr Crockett); and PharmaLogic Development, Inc, San Rafael, Calif (Dr Novack).
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Associations Between Near Work, Outdoor Activity, and Myopia Among Adolescent Students in Rural China: The Xichang Pediatric Refractive Error Study Report No. 2
Lu et al.
Arch Ophthalmol 2009;127:769-775.
ABSTRACT
| FULL TEXT
Effect of Progressive Addition Lenses on Myopia Progression in Japanese Children: A Prospective, Randomized, Double-Masked, Crossover Trial
Hasebe et al.
IOVS 2008;49:2781-2789.
ABSTRACT
| FULL TEXT
Form-Deprivation Myopia in Chick Induces Limited Changes in Retinal Gene Expression
McGlinn et al.
IOVS 2007;48:3430-3436.
ABSTRACT
| FULL TEXT
Parental History of Myopia, Sports and Outdoor Activities, and Future Myopia
Jones et al.
IOVS 2007;48:3524-3532.
ABSTRACT
| FULL TEXT
Three-dimensional modeling of the human eye based on magnetic resonance imaging.
Singh et al.
IOVS 2006;47:2272-2279.
ABSTRACT
| FULL TEXT
|